Phebra Signs International Distribution Agreement For Manufacture And Supply Of A New Pharmaceutical For Treatment Of Duchenne Muscular Dystrophy

Phebra is pleased to announce that it has signed an agreement with Michigan-based Phrixus Pharmaceuticals Inc. (‘Phrixus’) to manufacture and distribute (Carmeseal-MD™) and to assist Phrixus with its clinical trials. This new drug from Phrixus is expected to aid Duchenne muscular dystrophy (DMD) in patients suffering cardiac and respiratory deficits.